Prediction on liver fibrosis using different APRI thresholds when patient age is a categorical marker in patients with chronic hepatitis B

Clinica Chimica Acta

Volumn 412, Issue 1-2, 2011, Pages 33-37

  Liu, Hong Bo ^a   Zhou, Jian Ping ^a   Zhang, Yong ^a   Lv, Xiao Hui ^a   Wang, Wei ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b The Sixth People's Hospital of Shenyang City   (China)

Author keywords

Aspartate aminotransferase; Chronic hepatitis B; Fibrosis; Liver biopsy; Noninvasive marker

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ASPARTATE AMINOTRANSFERASES; BLOOD PLATELETS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LABORATORIES; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; TIME FACTORS; YOUNG ADULT;

EID: 78650515011     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.08.032     Document Type: Article

References (39)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
2. Alam M.M., Zaidi S.Z., Malik S.A., et al. Serology based disease status of Pakistani population infected with Hepatitis B virus. BMC Infect Dis 2007, 7:64.
3. Dienstag J.L., Goldin R.D., Heathcote E.J. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105-117.
4. Lai C.L., Yuen M.F. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007, 147:58-61.
5. Fattovich G., Bortolotti F., Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008, 48:335-352.
6. Saadeh S., Cammell G., Carey W.D., Younossi Z., Barnes D., Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001, 33:196-200.
7. Piccinino F., Sagnelli E., Pasquale G., Giutsi G. Complication following percutaneous liver biopsy: a multicentre retrospective study on 68, 276 biopsies. J Hepatol 1986, 2:165-173.
8. Bravo A.A., Sheth S.G., Chopra S. Liver biopsy. N Engl J Med 2001, 344:495-500.
9. Halfon P., Munteanu M., Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroentérol Clin Biol 2008, 32:22-39.
10. Sebastiani G., Vario A., Guido M., Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007, 13:525-531.
11. Ngo Y., Benhamou Y., Thibault V., et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS ONE 2008, 2(3):e2573.
12. Zeng M.D., Lu L.G., Mao Y.M., et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005, 42:1437-1445.
13. Hui A.Y., Chan H.L., Wong V.W., et al. Identification of chronic hepatitis B patients without signification liver fibrosis by a simple noninvasive model. Am J Gastroenterol 2005, 100:616-623.
14. Wu S.D., Wang J.Y., Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. World J Gastroenterol 2010, 16:501-507.
15. Cales P., Oberti F., Michalak S., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42:1373-1381.
16. Kim B.K., Kim S.A., Park Y.N., et al. Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver Int 2007, 27:969-976.
17. Kim B.K., Kim D.Y., Park J.Y., et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int 2010, 30:546-553.
18. Lin C.S., Chang C.S., Yang S.S., Yeh H.Z., Lin C.W. Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Internal Med 2008, 47:569-575.
19. Shin W.G., Park S.H., Jang M.K., et al. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008, 40:267-274.
20. Vardar R., Vardar E., Demiri S., et al. Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis?. Hepatogastroenterology 2009, 56:1459-1465.
21. Mallet V., Dhalluin-Venier V., Roussin C., et al. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2009, 29:409-415.
22. Giannini E., Botta F., Fasoli A., et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999, 44:1249-1253.
23. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
24. Poynard T., Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997, 4:199-208.
25. Sterling R.K., Lissen E., Clumeck N., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV / HCV coinfection. Hepatology 2006, 43:1317-1325.
26. Bedossa P., Poynard T. An algorithm for grading of activity in chronic hepatitis C. The METAVIR co-operative study group. Hepatology 1996, 24:289-293.
27. Myers R.P., Tainturier M.H., Ratziu V., et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003, 39:222-230.
28. Hanley H.A., McNeil B.J. The meaning and the use of the area under the receiver operating characteristic (ROC) curve. Radiology 1982, 142:29-36.
29. Little A.F., Ferris J.V., Dodd G.D., Baron R.L. Image-guided percutaneous hepatic biopsy: effect of ascites on the complication rate. Radiology 1996, 199:79-83.
30. Lindor K.D., Bru C., Jorgensen R.A., et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996, 23:1079-1083.
31. Afdhal N.H., Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004, 99:1160-1174.
32. Bedossa P., Dargère D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
33. Sebastiani G., Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006, 12:3682-3694.
34. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
35. Kamimoto Y., Horiuchi S., Tanase S., Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985, 5(3):367-375.
36. Aster R.H. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966, 45(5):645-657.
37. Zhang Y.X., Wu W.J., Zhang Y.Z., Feng Y.L., Zhou X.X., Pan Q. Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B. World J Gastroenterol 2008, 14:7117-7121.
38. Wai C.T., Cheng C.L., Wee A., et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006, 26:666-672.
39. Jhaveri R., Murray N. An omission in the AASLD Practice Guidelines on Chronic Hepatitis B. Hepatology 2007, 45(2):507-539.